{"id":"NCT02979535","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®","officialTitle":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-16","primaryCompletion":"2019-03-25","completion":"2019-03-25","firstPosted":"2016-12-01","resultsPosted":"2020-03-09","lastUpdate":"2022-03-25"},"enrollment":480,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever","Dengue Hemorrhagic Fever","Human Papillomavirus Disease"],"interventions":[{"type":"BIOLOGICAL","name":"CYD Dengue Vaccine","otherNames":["Dengvaxia®"]},{"type":"BIOLOGICAL","name":"CYD Dengue Vaccine","otherNames":["Dengvaxia®"]},{"type":"BIOLOGICAL","name":"Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant","otherNames":["Cervarix®"]},{"type":"BIOLOGICAL","name":"Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant","otherNames":["Cervarix®"]}],"arms":[{"label":"CYD Dengue Vaccine + Cervarix (Concomitant Administration)","type":"EXPERIMENTAL"},{"label":"CYD Dengue Vaccine + Cervarix (Sequential Administration)","type":"EXPERIMENTAL"}],"summary":"The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.\n\nPrimary objectives:\n\n* To demonstrate that the humoral immune response (in terms of geometric mean titers \\[GMTs\\]) to Cervarix after concomitant administration with the CYD dengue vaccine is non-inferior to the humoral immune response (in terms of GMTs) after sequential administration with the CYD dengue vaccine measured 28 days after the last dose of Cervarix.\n* To demonstrate that the humoral immune response (in terms of GMTs) to the CYD dengue vaccine after concomitant administration with Cervarix is non-inferior to the humoral immune response (in terms of GMTs) to the CYD dengue vaccine after sequential administration with Cervarix measured 28 days after the last dose of the CYD dengue vaccine.\n\nSecondary Objectives:\n\n* To demonstrate that the humoral immune response (in terms of seroconversion) to Cervarix after concomitant administration with the CYD dengue vaccine is non-inferior to the humoral immune response (in terms of seroconversion) to Cervarix sequential administration with the CYD dengue vaccine measured 28 days after the last dose of Cervarix.\n* To describe the humoral immune response to Cervarix at baseline and after each dose of Cervarix in each and any group.\n* To describe the humoral immune response to the CYD dengue vaccine at baseline and after each dose of the CYD dengue vaccine, in each and any group.\n* To describe the safety of Cervarix and CYD dengue vaccine after each and any dose in each group.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously Dengue Seropositive Participants","timeFrame":"28 days after the last Cervarix vaccination","effectByArm":[{"arm":"CYD Dengue Vaccine + Cervarix (Concomitant Administration)","deltaMin":2149,"sd":null},{"arm":"CYD Dengue Vaccine + Cervarix (Sequential Administration)","deltaMin":2268,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":1,"countries":["Mexico"]},"refs":{"pmids":["33992441"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":237},"commonTop":["Injection Site Pain","Myalgia","Malaise","Headache","Asthenia"]}}